Alterity Therapeutics Future Growth

Future criteria checks 2/6

Alterity Therapeutics's earnings are forecast to decline at 3.7% per annum while its annual revenue is expected to grow at 47.8% per year. EPS is expected to decline by 6% per annum. Return on equity is forecast to be -195.1% in 3 years.

Key information

-3.7%

Earnings growth rate

-5.96%

EPS growth rate

Biotechs earnings growth	25.2%
Revenue growth rate	47.8%
Future return on equity	-195.14%
Analyst coverage	Low
Last updated	30 Apr 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Aug 25

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Alterity Therapeutics (NASDAQ:ATHE) said its phase 2 trial of ATH434 to treat patients with Multiple System Atrophy (MSA) was open for enrolment in the U.K. "In a short period of time we have now commenced enrolment in our second region, and we look forward to broadening our reach over the next several months," said Alterity CEO David Stamler. In July, the company had said it dosed the first patient in New Zealand in the phase 2 study. The trial is expected to enroll ~60 adult patients who will either receive one of two dose levels of ATH434 or placebo for one year. MSA is a rare disorder of the nervous system which causes gradual damage to nerve cells in the brain and can affect breathing, digestion and bladder control.

Seeking Alpha • Jul 06

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Alterity Therapeutics (NASDAQ:ATHE) said the first patient was dosed in a a phase 2 trial of ATH434 in Multiple System Atrophy (MSA) MSA is a rare disorder of the nervous system which causes gradual damage to nerve cells in the brain and can affect breathing, digestion and bladder control. The trial is expected to enroll ~60 adult patients who will either receive one of two doses of ATH434 or placebo for one year.

Seeking Alpha • Sep 16

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Alterity has been granted notice of allowance by USPTO for a new group of iron chaperones that redistribute excess iron in neurodegenerative diseases. The Company’s iron chaperone technology has decent potential. The Company’s ATH434 is a promising candidate with initial focus on MSA.

Earnings and Revenue Growth Forecasts

NasdaqCM:ATHE - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2028	6	-46	-72	-51	3
6/30/2027	2	-35	-35	-27	3
6/30/2026	5	-18	-14	-14	3
12/31/2025	7	-15	-14	-14	N/A
9/30/2025	6	-13	-13	-13	N/A
6/30/2025	5	-12	-11	-11	N/A
3/31/2025	5	-16	-14	-14	N/A
12/31/2024	4	-20	-16	-16	N/A
9/30/2024	4	-19	-15	-15	N/A
6/30/2024	4	-19	-13	-13	N/A
3/31/2024	4	-16	-14	-14	N/A
12/31/2023	3	-12	-15	-15	N/A
9/30/2023	4	-13	-17	-17	N/A
6/30/2023	4	-14	-20	-20	N/A
3/31/2023	5	-14	-17	-17	N/A
12/31/2022	5	-14	-14	-14	N/A
9/30/2022	5	-14	-13	-13	N/A
6/30/2022	5	-13	-12	-12	N/A
3/31/2022	5	-13	-16	-16	N/A
12/31/2021	5	-13	-19	-19	N/A
9/30/2021	5	-14	-18	-18	N/A
6/30/2021	4	-15	-17	-17	N/A
3/31/2021	2	-16	-16	-16	N/A
12/31/2020	0	-16	-14	-14	N/A
9/30/2020	0	-15	-12	-12	N/A
6/30/2020	N/A	-13	-9	-9	N/A
3/31/2020	2	-13	-9	-9	N/A
12/31/2019	4	-13	-9	-9	N/A
9/30/2019	5	-12	N/A	-12	N/A
6/30/2019	5	-12	N/A	-14	N/A
3/31/2019	5	-11	N/A	-13	N/A
12/31/2018	4	-10	N/A	-12	N/A
9/30/2018	4	-9	N/A	-9	N/A
6/30/2018	3	-8	N/A	-6	N/A
3/31/2018	3	-8	N/A	-6	N/A
12/31/2017	3	-8	N/A	-6	N/A
9/30/2017	3	-8	N/A	-6	N/A
6/30/2017	3	-8	N/A	-6	N/A
3/31/2017	4	-8	N/A	-3	N/A
12/31/2016	4	-9	N/A	-1	N/A
9/30/2016	4	-8	N/A	-4	N/A
6/30/2016	5	-8	N/A	-7	N/A
3/31/2016	5	-8	N/A	-9	N/A
12/31/2015	6	-7	N/A	-10	N/A
9/30/2015	6	-7	N/A	-10	N/A
6/30/2015	6	-6	N/A	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATHE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATHE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATHE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATHE's revenue (47.8% per year) is forecast to grow faster than the US market (11.7% per year).

High Growth Revenue: ATHE's revenue (47.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ATHE is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/18 18:12
End of Day Share Price	2026/05/15 00:00
Earnings	2025/12/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alterity Therapeutics Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
George Zavoico	B. Riley Securities, Inc.
Madeleine Williams	Canaccord Genuity
Aydin Huseynov	Ladenburg Thalmann & Company

Alterity Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Alterity Therapeutics Announces Utility of Quantitative Mri as Biomarker for Multiple System Atrophy

Alterity Therapeutics Receives Positive FDA Feedback on Ath434 Phase 3 Program in Multiple System Atrophy

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

Alterity Therapeutics Limited Appoints Ann Cunningham as Independent Non-Executive Director, Effective April 17, 2026

Alterity Therapeutics Limited Receives Positive FDA Feedback on Ath434 Phase 3 Program

Alterity Therapeutics Limited Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, Effective March 2026

Alterity Therapeutics Limited Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Alterity Therapeutics Presents Promising Impact of Ath434 on Orthostatic Hypotension and Disease Progression in Msa At the 36Th International Symposium on the Autonomic Nervous System

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial At the 2025 International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Limited, Annual General Meeting, Nov 21, 2025

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the BioMUSE Natural History Study

Alterity Therapeutics Limited Prominently Featured at the International MSA Congress

Alterity Therapeutics Grants U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Alterity Therapeutics Presents Encouraging New Data from Its Ath434 Phase 2 Trial in Multiple System Atrophy At the American Academy of Neurology Annual Meeting

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million.

Alterity Therapeutics Limited Completes Last Patient Visit in Open-Label Trial

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 40.7 million.

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.118724 million.

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led by Robust Clinical Efficacy

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Limited Announces Management Changes

Alterity Therapeutics Limited Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Alterity Therapeutics Limited, Annual General Meeting, Nov 22, 2024

Alterity Therapeutics Limited Announces Chief Financial Officer Changes

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.

Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited Announces CFO Changes

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023

Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and Austria

Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's Disease

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy